Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

1.43
-0.1950-12.04%
Volume:2.43M
Turnover:3.64M
Market Cap:32.29M
PE:-0.11
High:1.61
Open:1.50
Low:1.39
Close:1.62
52wk High:10.99
52wk Low:1.39
Shares:22.66M
Float Shares:15.77M
Volume Ratio:37.22
T/O Rate:15.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.10
PE(LYR):-0.08

Loading ...

Karyopharm Plans to Submit Snda for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway

THOMSON REUTERS
·
Jul 31

Karyopharm Therapeutics - to Request Priority Review with Snda Submission for Selinexor Plus Ruxolitinib

THOMSON REUTERS
·
Jul 31

Karyopharm Plans August sNDA Filing Seeking FDA Priority Review for Selinexor-ruxolitinib in Myelofibrosis

Reuters
·
Jul 31

Karyopharm Says Phase 3 Selinexor Maintenance Trial in Endometrial Cancer Misses PFS Endpoint

Reuters
·
Jul 31

Karyopharm Therapeutics - no New Safety Signals Observed for Selinexor in Phase 3 Trial

THOMSON REUTERS
·
Jul 31

Karyopharm Therapeutics - to Reduce Planned Investment in Endometrial Cancer Program

THOMSON REUTERS
·
Jul 31

Karyopharm Therapeutics - Phase 3 Xport-Ec-042 Trial Does not Meet Primary Endpoint

THOMSON REUTERS
·
Jul 31

NASDAQ Trade Halt Halt News Pending at 04:01 Pm

Reuters
·
Jul 31

Karyopharm sinks after revealing executive cash retention program

TIPRANKS
·
Jul 21

RBC says Karyopharm weakness after compensation plan a buying opportunity

TIPRANKS
·
Jul 21

Stocks to Wtach: Karyopharm Therapeutics, Mkdwell, Advanced Biomed

Dow Jones
·
Jul 18

Karyopharm Therapeutics Slides on Disclosure of Cash-retention Program for Executives

Dow Jones
·
Jul 18

Karyopharm Grants 1,649 Rsus to Four New Hires Under Inducement Plan

Reuters
·
Jul 02

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 02

Analysts Are Bullish on These Healthcare Stocks: BioAge Labs, Inc. (BIOA), Karyopharm Therapeutics (KPTI)

TIPRANKS
·
Jun 17

Karyopharm posts Phase 3 SENTRY trial presentation on selinexor plus ruxolitinib in myelofibrosis

Reuters
·
Jun 14

Karyopharm posts endometrial cancer treatment landscape presentation

Reuters
·
Jun 09

Karyopharm joins Cantor-hosted webcast featuring endometrial cancer KOL Robert Coleman

Reuters
·
Jun 04

Karyopharm says Phase 3 SENTRY trial selected for presentation at EHA 2026

TIPRANKS
·
Jun 03

Karyopharm to Report Data From Phase 3 Trial of Selinexor Plus Ruxolitinib in Myelofibrosis

MT Newswires Live
·
Jun 02